Audentes Therapeutics

Two patients die in now-halted study of Audentes gene therapy
Two patients die in now-halted study of Audentes gene therapy
BioPharma Dive
Audentes Therapeutics
gene therapy
patient deaths
clinical trials
AT132
myotubular myopathy
Flag link:
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Reuters
Astellas
Xyphos Biosciences
M&A
Audentes Therapeutics
Flag link:
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
gene therapy
Astellas
Audentes Therapeutics
M&A
Novartis
Medicines Company
Flag link:
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Reuters
Astellas
M&A
gene therapy
Audentes Therapeutics
Flag link:
More M&A Activity Expected Around AAV-Based Gene Therapies, Analyst Says
More M&A Activity Expected Around AAV-Based Gene Therapies, Analyst Says
BioSpace
gene therapy
M&A
Audentes Therapeutics
Regenxbio
Passage Bio
Flag link:
Highlights: American Society of Gene & Cell Therapy Meeting
Highlights: American Society of Gene & Cell Therapy Meeting
BioSpace
gene therapy
cell therapy
Audentes Therapeutics
MaxCyte
Moderna Therapeutics
Translate Bio
Homology Medicines
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Audentes to develop vectorized antisense therapies with Nationwide
Audentes to develop vectorized antisense therapies with Nationwide
BioCentury
Audentes Therapeutics
antisense
Flag link:
Biotechs launch an IPO blitz as Nasdaq stumbles out of the gate
Biotechs launch an IPO blitz as Nasdaq stumbles out of the gate
Fierce Biotech
biotech
IPOs
Editas Medicine
Syndax Pharma
Audentes Therapeutics
Bavarian Nordic
Corvus Pharmaceuticals
Reata Pharmaceuticals
Flag link:
Gene Therapy's Big Comeback
Gene Therapy's Big Comeback
Forbes
gene therapy
Bristol-Myers Squibb
Bluebird Bio
NightstaRx
Voyager Therapeutics
uniQure
Celladon
Juno Therapeutics
Editas Medicine
Gensight Biologics
Audentes Therapeutics
Dimension Therapeutics
Flag link: